Issues
-
Cover Image
Cover Image
TORC1 inhibitors such as rapamycin have been tested in preclinical and clinical trials for cancer. One concern with these compounds is the potential for compensatory up-regulation of PI3K or Akt from TORC1 inhibition which can result from either TORC2 potentiation or relief of IRS1 repression downstream of S6K. Palomid 529 (P529) overcomes these obstacles by inhibiting both TORC1 and TORC2 and thus inhibiting both mTOR downstream signaling and AktS473 in both the tumor cells and vasculature. The cover images show that P529 inhibits the associations of mTOR with raptor (TORC1) and rictor (TORC2) and thus prevents the function of these complexes. Treatment of mice harboring a C6 glioma tumor inhibits overall tumor growth and this is accompanied by decreased vascular density (seen with CD31 staining) and decreased pAktS473 and pS6 staining in tumor cells and prominently tumor glomeruloid–like blood vessels. Thus, P529 represents a novel class of TORC1/2 inhibitor with efficacy in animal models of glioma and tumor angiogenesis. Further preclinical and clinical testing of this and other similar compounds are needed to establish whether TORC1/2 inhibition surpasses TORC1 inhibition in cancer therapy. For details, see the article by Xue and colleagues on page 9551 of this issue. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Reviews
Perspectives in Cancer Research
Priority Reports
Smokers with the CHRNA Lung Cancer–Associated Variants Are Exposed to Higher Levels of Nicotine Equivalents and a Carcinogenic Tobacco-Specific Nitrosamine
Cell, Tumor, and Stem Cell Biology
Serotonin Metabolism Is Dysregulated in Cholangiocarcinoma, which Has Implications for Tumor Growth
Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
Endocrinology
The Mitogen-Activated Protein Kinase Phosphatase Vaccinia H1–Related Protein Inhibits Apoptosis in Prostate Cancer Cells and Is Overexpressed in Prostate Cancer
Epidemiology
Experimental Therapeutics, Molecular Targets, and Chemical Biology
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Hypoxia-Mediated Induction of the Polyamine System Provides Opportunities for Tumor Growth Inhibition by Combined Targeting of Vascular Endothelial Growth Factor and Ornithine Decarboxylase
Antitumor Effect of SN-38–Releasing Polymeric Micelles, NK012, on Spontaneous Peritoneal Metastases from Orthotopic Gastric Cancer in Mice Compared with Irinotecan
A Human Antibody–Drug Conjugate Targeting EphA2 Inhibits Tumor Growth In vivo
Genetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer
SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of cIAP-1/2 and XIAP
Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells
Immunology
Type 2 Bias of T Cells Expanded from the Blood of Melanoma Patients Switched to Type 1 by IL-12p70 mRNA–Transfected Dendritic Cells
Molecular Biology, Pathobiology, and Genetics
Posttranscriptional Regulation of the Breast Cancer Susceptibility Gene BRCA1 by the RNA Binding Protein HuR
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
Prevention
Garlic Constituent Diallyl Trisulfide Prevents Development of Poorly Differentiated Prostate Cancer and Pulmonary Metastasis Multiplicity in TRAMP Mice
Systems Biology and Emerging Technologies
Identification of Alternative Splicing Markers for Breast Cancer
Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer
Tumor Microenvironment
ADAMTS-1 Metalloproteinase Promotes Tumor Development through the Induction of a Stromal Reaction In vivo
Corrections
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.